Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as LY900009 - Dose Escalation Phase (Part A)
LY900009 · 1 trial · 1 indication
Clinically significant effects are study drug related serious adverse events (SAEs) and study drug related treatment emergent adverse events (TEAEs). A summary of all SAEs and all other non-SAEs regardless of causality is located in the Reported Adverse Events module.
| Arm | Type | Description |
|---|---|---|
| LY900009 | EXPERIMENTAL | Dose escalation phase: 2 milligrams (mg), 4 mg, 8 mg, 15 mg, 30 mg, 45 mg and 60mg LY900009 administered orally 3 times per week (Monday, Wednesday, Friday) for 4 weeks of a 28-day cycle. Dose confirmation phase: 30 mg LY900009 administered orally 3 times per week (Monday, Wednesday, Friday) for 4 weeks of a 28-day cycle. Participants experiencing clinical benefit may continue treatment unless discontinuation criteria are met. |
| Name | Type | Description |
|---|---|---|
| LY900009 - Dose Escalation Phase (Part A) | DRUG | 2 milligrams (mg), 4 mg, 8 mg, 15 mg, 30 mg, 45 mg and 60mg LY900009 administered orally 3 times per week (Monday, Wednesday, Friday) for 4 weeks of a 28-day cycle. Participants experiencing clinical benefit may continue treatment unless discontinuation criteria are met. |
| LY900009 - Dose Confirmation Phase (Part B) | DRUG | 30 mg LY900009 orally 3 times per week (Monday, Wednesday, Friday) for 4 weeks of a 28-day cycle. Participants experiencing clinical benefit may continue treatment unless discontinuation criteria are met. |
Inclusion Criteria: * The participants must be, in the judgment of the investigator, an appropriate candidate for experimental therapy after available standard therapies have ceased to provide clinical benefit for their disease. * The participants must have histological or cytological evidence of c...
Top 2 of 4 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/GEH200521 |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
LY900009- Dose Escalation Phase is the Phase 1 dose escalation portion of a clinical program evaluating LY900009 in adults with advanced cancer. It is also known as LY900009 - Dose Escalation Phase (Part A). The study enrolled 35 participants in the United States and has been completed.
LY900009- Dose Escalation Phase was studied in adults with advanced cancer. The trial was an uncontrolled, non-randomized Phase 1 study designed to evaluate the drug in this patient population. No efficacy or approval claims are made here; the program has completed its single listed trial.
LY900009- Dose Escalation Phase is developed by Eli Lilly and Company, which trades under the ticker LLY. Eli Lilly sponsored the Phase 1 trial NCT01158404, titled Notch Inhibitor in Advanced Cancer, which evaluated the drug in participants with advanced cancer.
LY900009- Dose Escalation Phase is in Phase 1. The single listed trial, NCT01158404, is a completed Phase 1 study with 35 participants. The drug is investigational and has not been approved for any indication based on the available information.
LY900009- Dose Escalation Phase has been evaluated in one clinical trial: NCT01158404, titled Notch Inhibitor in Advanced Cancer. This Phase 1 trial enrolled 35 adults aged 18 years and older in the United States and is now completed.
Yes, LY900009- Dose Escalation Phase is also known as LY900009 - Dose Escalation Phase (Part A). The two names refer to the same Phase 1 dose escalation study of LY900009 in advanced cancer, developed by Eli Lilly and Company.